Table 1.
Current clinical trials evaluating B-cell therapies in SLE and LN
| Target | Drug | Study title | Study status | Disease target | Study phase | Identifier |
|---|---|---|---|---|---|---|
| CD20 | Rituximab (anti-CD20 mAb) | Rituximab objective outcome measures trial in SLE | Recruiting | SLE | Phase 2 | NCT03054259 |
| RING | Recruiting | LN | Phase 3 | NCT01673295 | ||
| Obinutuzumab (anti-CD20 mAb) | A study to evaluate the safety and efficacy of obinutuzumab compared with placebo in participants with LN | Recruiting | LN | Phase 2 | NCT02550652 | |
| CD19 | XmAb5871 | A study of the effect of XmAb®5871 in patients with SLE | Active | SLE | Phase 2 | NCT02725515 |
| BAFF/APRIL | RC18 (TACI-antibody fusion protein) | Study of RC18 administered subcutaneously to subjects with SLE | Recruiting | SLE | Phase 2 | NCT02885610 |
| Belimumab (anti-BAFF) | Efficacy and safety of belimumab in patients with active LN | Active | LN | Phase 3 | NCT01639339 | |
| AMG 570 (bisepcific peptibody—BAFF and ICOS ligand) | Single ascending dose study of AMG 570 in healthy subjects | Active | SLE | Phase 1 | NCT02618967 | |
| Immunoproteasome | KZR-616 | A study of KZR-616 in patients with SLE with and without nephritis | Recruiting | SLE | Phase 1/2 | NCT03393013 |
| Combination | Rituximab, belimumab | Rituximab and belimumab for LN | Active | LN | Phase 2 | NCT02260934 |
| Synergetic B-cell immodulation in SLE | Recruiting | SLE | Phase 2 | NCT02284984 | ||
| A study to evaluate the efficacy and safety of belimumab administered in combination with rituximab to adult subjects with SLE–BLISS–BELIEVE | Recruiting | SLE | Phase 3 | NCT03312907 |